Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome.

Link to article at PubMed

Related Articles

Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome.

Chest. 2018 Apr 26;:

Authors: Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA, Mara KC, Limper AH

Abstract
BACKGROUND: Evidence supporting adjunctive corticosteroids during the treatment of Pneumocystis pneumonia (PcP) in adults without human immunodeficiency virus (HIV) is minimal and controversial.
METHODS: This retrospective cohort study included PcP-positive, hospitalized patients without HIV admitted to Mayo Clinic from 2006 to 2016. Change from baseline in the respiratory component of the Sequential Organ Failure Assessment score (SOFAresp) at day 5 was compared between early (within 48 hours) steroid recipients and non-recipients utilizing multivariable logistic regression and in a propensity-matched analysis.
RESULTS: Among the 323 included patients (early steroids, N = 258; no steroids, N = 65), the median (IQR) age was 65 (53, 73) years, 63% were male, and 92% were Caucasian. Severity-adjusted regression and propensity-matched analyses demonstrated early steroids were associated with less improvement in SOFAresp at day 5 compared to no steroids, p = 0.001 and p = 0.017, respectively. No differences were observed in the odds of having a ≥ one-point improvement in SOFAresp at day 5 compared to baseline between groups (adjusted OR 0.76, 95% CI 0.24, 2.28; p = 0.61). Overall 30-day mortality was 22.9% (95% CI 18.2%, 27.4%). No differences in mortality, length of stay, admission to the ICU, or need for mechanical ventilation were found between early steroid recipients and non-recipients.
CONCLUSIONS: The addition of early corticosteroids to anti-Pneumocystis therapy in patients without HIV was not associated with improved respiratory outcomes.

PMID: 29705221 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.